X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9) 9
female (6) 6
oncology (5) 5
adult (4) 4
index medicus (4) 4
male (4) 4
middle aged (4) 4
aged (3) 3
antibodies, monoclonal - immunology (3) 3
cancer (3) 3
chemotherapy (3) 3
adjuvant treatment (2) 2
aged, 80 and over (2) 2
bone marrow - immunology (2) 2
breast cancer (2) 2
breast neoplasms - drug therapy (2) 2
breast neoplasms - genetics (2) 2
breast neoplasms - pathology (2) 2
carcinoma, small cell - immunology (2) 2
cell line (2) 2
clinical trials (2) 2
disease progression (2) 2
erbb-2 protein (2) 2
fluorescent antibody technique (2) 2
health aspects (2) 2
hematopoietic stem cells - immunology (2) 2
lung neoplasms - immunology (2) 2
neoadjuvant therapy (2) 2
neoplasm staging (2) 2
pathological complete response (2) 2
prognosis (2) 2
receptor, erbb-2 - genetics (2) 2
research (2) 2
survival rate (2) 2
therapy (2) 2
treatment outcome (2) 2
5-fluorouracil (1) 1
academic medical centers (1) 1
acetylcysteine (1) 1
adjuvant trastuzumab (1) 1
advanced solid tumors (1) 1
agent (1) 1
analysis (1) 1
angiogenesis (1) 1
animals (1) 1
anthracycline (1) 1
anthracyclines (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, neoplasm - immunology (1) 1
antibody-dependent cell cytotoxicity (1) 1
antigens, neoplasm - analysis (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
antitumor-activity (1) 1
biomarkers (1) 1
bone marrow - pathology (1) 1
bone marrow transplantation (1) 1
breast - drug effects (1) 1
breast - pathology (1) 1
breast neoplasms - epidemiology (1) 1
bridged-ring compounds - administration & dosage (1) 1
bridged-ring compounds - adverse effects (1) 1
cancer care facilities (1) 1
carboplatin - therapeutic use (1) 1
carcinoma (1) 1
carcinoma, non-small-cell lung - drug therapy (1) 1
carcinoma, small cell - pathology (1) 1
carcinoma, small cell - therapy (1) 1
care and treatment (1) 1
cfu-gm (1) 1
chemotherapy, adjuvant (1) 1
chi-square distribution (1) 1
clinical medicine (1) 1
clinical-trials (1) 1
collaboratives (1) 1
colony-forming units assay (1) 1
colorectal neoplasms - diagnosis (1) 1
colorectal neoplasms - pathology (1) 1
combination (1) 1
combined modality therapy (1) 1
complement system proteins - immunology (1) 1
concurrent (1) 1
contrast agents (1) 1
culture media (1) 1
cycle (1) 1
cyclophosphamide (1) 1
cyclophosphamide - administration & dosage (1) 1
cyclophosphamide - adverse effects (1) 1
cytotoxicity, immunologic (1) 1
diagnostic imaging (1) 1
diarrhea (1) 1
diffuse optical spectroscopy (1) 1
disease-free survival (1) 1
docetaxel (1) 1
dolastatin 10 (1) 1
dolastatin-10 (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1986, DM, Disease-a-month, Volume 32, no. 10., 594-652.
Book
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 6/2018, Volume 169, Issue 2, pp. 333 - 340
The purpose of this two-cohort Phase II trial was to estimate the pathologic complete response (pCR: ypT0/is ypN0) rate when trastuzumab plus pertuzumab are... 
Neoadjuvant therapy | HER-2-positive | Medicine & Public Health | Pertuzumab | Pathological complete response | Oncology | Breast cancer | Trastuzumab | MULTICENTER | OPEN-LABEL | COMBINATION | PLUS TRASTUZUMAB | CHEMOTHERAPY | ADJUVANT TRASTUZUMAB | LAPATINIB | THERAPY | ONCOLOGY | CLINICAL-TRIALS | CONCURRENT | Cyclophosphamide - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Epirubicin - administration & dosage | Cyclophosphamide - adverse effects | Drug-Related Side Effects and Adverse Reactions - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Adult | Female | Paclitaxel - administration & dosage | Taxoids - adverse effects | Breast Neoplasms - epidemiology | Antibodies, Monoclonal, Humanized - adverse effects | Paclitaxel - adverse effects | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Neoadjuvant Therapy - adverse effects | Bridged-Ring Compounds - adverse effects | Bridged-Ring Compounds - administration & dosage | Drug-Related Side Effects and Adverse Reactions - classification | Epirubicin - adverse effects | Anthracyclines | Cyclophosphamide | Analysis | Adjuvant treatment | Clinical trials | Product development | Health aspects | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4_suppl, pp. 630 - 630
630 Background: TAS-102 is an oral combination of the anti-metabolite 5-trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI), preventing the... 
Journal Article
Journal Article
Oncology Times, ISSN 0276-2234, 10/2007, Volume 29, Issue 20, pp. 3 - 3
Journal Article
Community Oncology, ISSN 1548-5315, 2008, Volume 5, Issue 9, pp. 516 - 524
Although the prognosis for patients with advanced disease has improved significantly over the past 2 decades, most still die of uncontrollable disease. Once a... 
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 2008, Volume 26, Issue 19, pp. 3213 - 3221
Purpose: As treatment options expand for metastatic colorectal cancer (mCRC), a blood marker with a prognostic and predictive role could guide treatment. We... 
METIS-251916
Journal Article
Leukemia Research, ISSN 0145-2126, 1984, Volume 8, Issue 4, pp. 521 - 534
Journal Article
Scandinavian Journal of Haematology, ISSN 0036-553X, 09/1985, Volume 35, Issue 3, pp. 251 - 256
Journal Article
Cancer Research, ISSN 0008-5472, 1986, Volume 46, Issue 4, pp. 2077 - 2084
The reactivity of the murine immunoglobulin monoclonal antibody LAM8 directed against a membrane antigen of human small cell carcinoma (SCC) of the lung was... 
Cell Line | Molecular Weight | Humans | Immunoglobulin M - immunology | Immunoenzyme Techniques | Carcinoma, Small Cell - immunology | Lung Neoplasms - immunology | Radioimmunoassay | Fluorescent Antibody Technique | Histocytochemistry | Antigens, Neoplasm - analysis | Antibodies, Monoclonal - immunology | Cytotoxicity, Immunologic
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.